NDAINJECTIONINJECTABLE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
ZEMURON (rocuronium bromide) by Merck & Co. is duration. Approved for neuromuscular blockade, anesthesia, surgery. First approved in 1994.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEMURON (rocuronium bromide) is a non-depolarizing neuromuscular blocking agent administered via injection during anesthesia and surgery. It works by competing for cholinergic receptors at the motor end-plate, with effects reversible by acetylcholinesterase inhibitors like neostigmine. The drug enables muscle relaxation during surgical procedures and anesthetic management.
LOE Approaching
As LOE approaches, the brand team is likely consolidating efforts and managing market decline; expect smaller team size and focus on operational efficiency rather than growth initiatives.
Mechanism of Action
duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Indications (3)
Worked on ZEMURON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.